An afternoon dose also yielded significantly better overnight (10 p.m. to 4 a.m.) suppression in blood eosinophil counts as a marker of airway inflammation compared with the other two groups, although ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with ...

GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma, denying a label extension because there was no evidence to show a reduction of flare-ups.

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

The dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...

GSK announced two important endorsements from the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...